Cipher Pharmaceuticals Reports Adjusted EBITDA1 of $1.2 million in Q3 2016

- November 11th, 2016

Cipher Pharmaceuticals (NASDAQ:CPHR,TSX:CPH) announced its financial and operational results for Q3 2016. As quoted in the press release: Financial Highlights for Q3 2016 (all figures compared to Q3 2015, unless otherwise noted) Total revenue of $9.3 million, an increase of 10% from $8.5 million in Q3 2015. Licensing revenue of $6.8 million, an increase of … Continued

Cipher Pharmaceuticals (NASDAQ:CPHR,TSX:CPH) announced its financial and operational results for Q3 2016.
As quoted in the press release:

Financial Highlights for Q3 2016
(all figures compared to Q3 2015, unless otherwise noted)

  • Total revenue of $9.3 million, an increase of 10% from $8.5 million in Q3 2015.
  • Licensing revenue of $6.8 million, an increase of 9% over $6.3 million in Q3 2015.
  • Canadian product revenue of $1.0 million, up 67% from $0.6 million in Q3 2015.
  • U.S. product revenue of $1.5 million, compared with $1.6 million in Q3 2015.
  • Net loss of $21.8 million, or $0.81 per basic share, which includes a non-cash impairment charge on intangible assets of $17.3 million and on goodwill of $2.3 million related to the Company’s U.S. segment.
  • Adjusted EBITDA1 of $1.2 million, compared with $1.9 million.
  • Excluding the impairment charge, net loss would have been $2.2 million, or $0.08 per basic share.
  • Net cash flow from operating activities of $2.0 million.
  • $30.6 million in cash and cash equivalents at quarter end, up from $27.2 million at year end.

Click here for the full press release

Find out what experts are saying about the future of cannabis

 
Read our 2019 conference report today
 

Tags

Tags:

Leave a Reply